POLISH NEUROLOGICAL SOCIETY COMMISSION OF NEUROCHEMISTRY COMMISSION FOR STUDY OF MULTIPLE SCLEROSIS

1968 ◽  
Vol 15 (8) ◽  
pp. 882-882
Keyword(s):  
Multiple Sclerosis ◽  
Neurological Society

scholarly journals Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report

2021 ◽  
Vol 49 (9) ◽  
pp. 030006052110443
Author(s):  
Hubert Mado ◽  
Katarzyna Kubicka-Bączyk ◽  
Monika Adamczyk-Sowa
Keyword(s):  
Multiple Sclerosis ◽  
Immune Response ◽  
Case Report ◽  
Severe Acute Respiratory Syndrome ◽  
Immune Responses ◽  
B Lymphocyte ◽  
Neurological Society ◽  
Antibody Responses ◽  
Post Vaccination ◽  
Lymphocyte Depletion

Patients with multiple sclerosis (MS) repeatedly receive therapies that cause B-lymphocyte depletion. This may lead to abnormal immune responses following coronavirus disease 2019 (COVID-19) vaccination, as has been suggested previously. We therefore evaluated post-vaccination immune responses in a patient with MS treated with ocrelizumab. The intervals between ocrelizumab infusions and vaccination were as recommended by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. A reactive immune response was observed in this patient following vaccination. This suggests that appropriate intervals between ocrelizumab infusions and COVID-19 vaccinations may permit the generation of efficacious immune responses in patients receiving B-lymphocyte depleting therapies.

Microglia-derived macrophages in early multiple sclerosis plaques

1996 ◽  
Vol 22 (3) ◽  
pp. 207-215 ◽  
Author(s):  
H. Li ◽  
M. L. Cuzner ◽  
J. Newcombe
Keyword(s):  
Multiple Sclerosis
Sign in / Sign up

Export Citation Format

Share Document